Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-06-13
2006-06-13
Romeo, David (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
07060680
ABSTRACT:
Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation normally associated with ulcerative diseases, and (4) stimulating the repair of ulcerative lesions and the regeneration of the luminal tissue. The methods and compositions include a therapeutically effective amount of a morphogen as defined herein.
REFERENCES:
patent: 4806523 (1989-02-01), Bentz et al.
patent: 4877864 (1989-10-01), Wang et al.
patent: 4919939 (1990-04-01), Baker
patent: 4968590 (1990-11-01), Kuberasampath et al.
patent: 4971952 (1990-11-01), Bentz et al.
patent: 4975526 (1990-12-01), Kuberasampath et al.
patent: 4983581 (1991-01-01), Antoniades et al.
patent: 5008240 (1991-04-01), Bentz et al.
patent: 5011691 (1991-04-01), Oppermann et al.
patent: 5013649 (1991-05-01), Wang et al.
patent: 5043329 (1991-08-01), Lichtenberger
patent: 5091513 (1992-02-01), Huston et al.
patent: 5102870 (1992-04-01), Florine et al.
patent: 5106626 (1992-04-01), Parsons et al.
patent: 5108753 (1992-04-01), Kuberasampath et al.
patent: 5108989 (1992-04-01), Amento et al.
patent: 5110795 (1992-05-01), Hahn
patent: 5118791 (1992-06-01), Burnier et al.
patent: 5135915 (1992-08-01), Czarniecki et al.
patent: 5141905 (1992-08-01), Rosen et al.
patent: 5171579 (1992-12-01), Ron et al.
patent: 5234908 (1993-08-01), Szabo et al.
patent: 5236456 (1993-08-01), O'Leary et al.
patent: 5645591 (1997-07-01), Kuberasampath et al.
patent: 5656593 (1997-08-01), Kuberasampath et al.
patent: 5733878 (1998-03-01), Kuberasampath et al.
patent: 0148155 (1985-07-01), None
patent: 0269408 (1988-06-01), None
patent: 0416578 (1991-03-01), None
patent: 84/01106 (1984-03-01), None
patent: 88/00205 (1988-01-01), None
patent: 89/09787 (1989-10-01), None
patent: 89/09788 (1989-10-01), None
patent: 89/10409 (1989-11-01), None
patent: 90/00900 (1990-02-01), None
patent: 90/01941 (1990-03-01), None
patent: 90/03733 (1990-04-01), None
patent: 90/10018 (1990-09-01), None
patent: 90/11366 (1990-10-01), None
patent: 91/05802 (1991-05-01), None
patent: 91/18558 (1991-12-01), None
patent: 92/07073 (1992-04-01), None
patent: 92/09301 (1992-06-01), None
patent: 92/15323 (1992-09-01), None
patent: WO 93/04692 (1993-03-01), None
Rutherford et al. A new biological approach to vital pulp therapy. Crit Rev Oral Biol Med. 1995;6(3):218-29.
Alper. Ulcers as an Infectious Disease.Science260, 159-160 (1993).
Ayers. Molecular Cell Biology. Addison-Wesley Publishing Company. p. 803 (1989).
Baird et al. Inhibition of endothelial cell proliferation by type-beta transforming growth factor: interactions with acidic and basic fibroblast growth factors.Biochem. Biophys. Ress. Comm.138, 476-482 (1986).
Basler et al. Control of Cell Pattern in the Neural Tube: Regulation of Cell Differentiation by Dorsalin-1, a Novel TGFβ Family Member.Cell73, 687-702 (1993).
Beck et al. Accelerated healing of ulcer wounds in the rabbit ear by recombinant human transforming growth-beta 1.Growth Factors2, 273-282 (1990).
Behringer et al. Abnormal Sexual Development in Transgenic Mice Chronically Expressing Mullerian Inhibiting Substance.Nature345, 167-170 (1990).
Border et al. Suppression of Experimental Glomerulonephritis by Antiserum Against Transforming Growth Factor B1.Nature346, 371-374 (1990).
Border et al. Transforming Growth Factor-β in Disease: The Dark Side of Tissue Repair.J. Clin. Invest.90, 1-7 (1992).
Bowie et al. Deciphering the message in protein sequences: tolerance to amino acid substitutions.Science247, 1306-1310 (1990).
Caplan. Mesenchymal Stem Cells.J. Orthop. Res.9, 641-650 (1991).
Castilla et al. Transforming Growth Factors B1 and α in Chronic Liver Disease.The New England J. Med.324, 933-939 (1991).
Cate et al. Isolation of the Bovine and Human Genes for Mullerian Inhibiting Substance and Expression of the Human Gene in Animal Cells.Cell45, 685-698 (1998).
Celeste et al. Identification of Transforming Growth Factor Beta Family Members Present in Bone-Inductive Protein Purified from Bovine Bone.PNAS87, 9843-9847 (1990).
Cheifetz et al. A Surface Component on GH3 Pituitary Cells That Recognizes Transforming Growth Factor-B, Activin, and Inhibin.J. Biol. Chem.263, 17725-17728 (1988).
Chen et al. Bone Morphogenetic Protein-2b Stimulation of Growth and Osteogenic Phenotypes in Rat Osteoblast-like Cells: Comparison with TGF-B.J. Bone. Min. Res.6, 1387-1393 (1991).
Chomcuzaski et al. Single-step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction.Anal. Biochem.162, 156-159 (1987).
Clark et al. Coregulation of Collagenase and Collagenase Inhibitor Production by Phorbol Myristate Acetate in Human Skin Fibroblasts.Arch. Bio. Chem. Biophys.241, 36-44 (1985).
Coffman et al. Xotch, the Xenopus Homolog of Drosophila Notch.Science249, 1438-1441 (1990).
D'Allessandro et al.J. Cell. Biochem.Suppl. 15F (Abstr. No. 105), 1991.
Estevez et al. The daf-4 Gene Encodes a Bone Morphogenetic Protein Receptor Controlling C. Elegans Dauer Larva Development.Nature365, 644-649 (1993).
Fava et al. Transforming Growth Factor B1 (TGF-B1) Induced Neutrophil Recruitment to Synovial Tissues: Implications for TGF-B-driven Synovial Inflammation and Hyperplasia.J. Exp. Med.173, 1121-1132 (1991).
Fausto et al. Effects of TGF-βs in the Liver: Cell Proliferation and Fibrogenesis.Ciba Found. Symp.157, 165-174 (1991).
Forage et al. Cloning and Sequence Analysis of cDNA Species Coding for the Two Subunits of Inhibin from Bovine Follicular Pluid.PNAS83, 3091-3095 (1986).
Gallagher. Oral Mucous Membrane Reactions to Drugs and ChemicalsCurr. Opin. Dent.1, 777-782 (1991).
Gennaro.Remington's Pharmaceutical Sciences(Mack Pubs, N. Y.), 1990.
George et al. Macromolecular Sequencing and Synthesis; Selected Methods and Applications. 12, 127-149 (1988).
Gray et al. Requirement for Activin A and Transforming Growth Factor-B1 Pro-Regions in Homodimer Assembly.Science247, 391-394 (1990).
Green et al. Graded Changes in Dose of Xenopus Activin A Homologue Elicit Stepwise Transitions in Embryonic Cell Fate.Nature347, 391-394 (1990).
Heath et al. Regulatory Factors of Embryonic Stem Cells.J. Cell Sci. Supp.10, 257-266 (1988).
Hebda et al. Stimulatory effects of transforming growth factor-beta and epidermal growth factor on epidermal cell outgrowth from porcine skin explant cultures.J. Invest. Dermatol.91, 440-445 (1988).
Israel et al. Abstract Q-111J. Cell Biochem.Suppl. (1991).
Israel et al. Expression and Characterization of Bone Morphogenetic Protein-2 in Chinese Hamster Ovary Cells.Growth Factors7, 139-150 (1992).
Joyce et al. Role of growth factors in fracture healing.Prog. Clin. Biol. Res.365, 391-416 (1991).
Katagiri et al. The Non-Osteogenic Mouse Pluripotent Cell Line, C3H10T1/2, is Induced to Differentiate Into Osteoblastic Cells by Recombinant Human Bone Morphogenetic Protein-2.Biochem. Biophys. Res. Comm.172, 295-299 (1990).
Khalil et al. Increased Production and Immunohistochimical Localization of Transforming Growth Factor-B in Idiopathic Pulmonary Fibrosis.Am. J. Respir. Cell Mol. Biol.5, 155-162 (1991).
Kingsley. The TGF-B Superfamily: New Members, New Receptors, and New Genetic Tests of Function in Different Organisms.Genes&Development8, 133-146 (1994).
Koenig et al. Characterization and Cloning of a Receptor for BMP-2 and BMP-4 from NIH 3T3 Cells.Mol. Cell. Biol.14, 5961-5974 (1994).
Krummel et al. Transforming Growth Factor Beta (TGF-B) Induces Fibrosis in a Fetal Wound Model.J. Pediatric Surgery23, 647-652 (1988).
Kuruvilla et al. Protective Effect of Transforming Growth Factor B1 on Experimental Autoimmune Diseases in Mice.PNAS88, 2918-2921 (1991).
Lee. Expression of Growth/Differentiation Factor 1 in the Nervous System: Conservation of a Bicistronic Structure.PNAS88, 4250-4254 (1991).
Lee. Identification of a Novel Member (GDF-1) of the Transforming Growth Factor-β Superfamily.Mol. Endocrinol.4, 1034-1040 (1990).
Lefer et al. Anti-Ischaemic and Endothelial Pro
Charette Marc F.
Cohen Charles M.
Kuberasampath Thangavel
Oppermann Hermann
Ozkaynak Engin
Curis, Inc.
Fish & Neave IP Group Ropes & Gray LLP
Romeo David
LandOfFree
Morphogen treatments for limiting proliferation of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Morphogen treatments for limiting proliferation of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Morphogen treatments for limiting proliferation of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3699704